Chemotherapy
8 videos · updated daily
7:33 GLEAM: Zolbetuximab in CLDN18.2-Positive Pancreatic Cancer
Dr. Wungki Park speaks to ecancer about the Phase II GLEAM study of zolbetuximab plus gemcitabine and nab-paclitaxel in CLDN18.2-positive metastatic pancreatic cancer, which did not meet its primary endpoint of improving overall survival.
39:29 ASCO 2026: Highlights and Analysis
Associate Professor Bishal Gyawali talks to ecancer about ASCO 2026 presentations across GI, pancreatic, lung, breast and prostate cancer, including daraxonrasib in metastatic pancreatic adenocarcinoma.
7:22 Emerging Trials in Ph+ ALL
Drs. Anand Patel and Leidy Isenalumhe discuss emerging clinical trials of asciminib and of ponatinib combined with blinatumomab or chemotherapy in Ph+ ALL, in an American Society of Hematology webinar supported by Amgen.
7:07 TRIPP-FFX: P-32 Microparticles and FOLFIRINOX in Pancreatic Cancer
Dr. Michele Milella of the University of Verona discusses the design and results of the randomised non-comparative TRIPP-FFX study of FOLFIRINOX with intratumoral phosphorus-32 microparticles in unresectable locally advanced pancreatic cancer.
32:11 SARC037 in Ewing Sarcoma with Dr. Patrick Grohar
Dr. Patrick Grohar of the University of Michigan discusses for SARC the development, conduct and Nature Medicine-published results of SARC037, a Phase 1/2 trial of trabectedin and low-dose irinotecan in relapsed or refractory Ewing sarcoma.
2:47 RenovoTAMP™: Trans-Arterial Micro-Perfusion Therapy Platform
RenovoRx on RenovoTAMP, a platform for delivering chemotherapy directly to hard-to-treat tumours, now in a Phase 3 trial in locally advanced pancreatic cancer.
1:20:51 CHARLIE'S Trial 2: HIPEC vs PIPAC in Appendix Cancer
Patrick Wagner, MD, and Shannon Altpeter, PA-C, of Allegheny Health Network introduce CHARLIE'S Trial 2, which compares laparoscopic HIPEC with PIPAC in patients with peritoneal disease who are not candidates for cytoreductive surgery.
4:41 The Innovation Behind RenovoRx's Therapy Platform
RenovoRx describes its trans-arterial micro-perfusion platform for delivering approved chemotherapy locally, and its lead candidate RenovoGem, being studied in the Phase 3 TIGeR-PaC trial in pancreatic cancer.